+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Endocrine And Metabolic Disorders Drugs Market Research Reports

Hunter Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Hunter Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Familial Chylomicronemia Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Familial Chylomicronemia Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Niemann Pick C Disease- Pipeline Insight, 2025 - Product Thumbnail Image

Niemann Pick C Disease- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Diabetic Ketoacidosis - Pipeline Insight, 2025 - Product Thumbnail Image

Diabetic Ketoacidosis - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Graves' Orbitopathy- Pipeline Insight, 2025 - Product Thumbnail Image

Graves' Orbitopathy- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Androgen Receptor Antagonists - Pipeline Insight, 2025 - Product Thumbnail Image

Androgen Receptor Antagonists - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
From
Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025 - Product Thumbnail Image

Sodium-glucose Transporter 2 Inhibitors - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Phosphoglucomutase (PGM 1) Deficiency - Pipeline Insight, 2025 - Product Thumbnail Image

Phosphoglucomutase (PGM 1) Deficiency - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Acid Sphingomyelinase Deficiency (ASMD) - Pipeline Insight, 2025 - Product Thumbnail Image

Acid Sphingomyelinase Deficiency (ASMD) - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Hypertriglyceridemia - Pipeline Insight, 2025 - Product Thumbnail Image

Hypertriglyceridemia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Adenosine A1 Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A1 Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Glucagon Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Glucagon Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A2A Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Beta Selective Thyroid Hormone Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2025 - Product Thumbnail Image

Fibroblast Growth Factor 1 (FGF-1) Inhibitor - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A2A Receptor Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A2A Receptor Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Adenosine A2 Receptor Antagonist - Pipeline Insight, 2025 - Product Thumbnail Image

Adenosine A2 Receptor Antagonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Loading Indicator

The Endocrine and Metabolic Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs used to treat endocrine and metabolic disorders. Endocrine disorders are conditions that affect the body's hormones, while metabolic disorders are conditions that affect the body's ability to process and use energy. Endocrine and metabolic disorders can include diabetes, thyroid disorders, obesity, and adrenal disorders. Endocrine and Metabolic Disorders Drugs are typically developed by pharmaceutical companies and are prescribed by physicians. These drugs can be used to treat a variety of endocrine and metabolic disorders, including diabetes, thyroid disorders, obesity, and adrenal disorders. Common drugs used to treat these conditions include insulin, metformin, and glucagon-like peptide-1 (GLP-1) agonists. Some of the major companies in the Endocrine and Metabolic Disorders Drugs market include Novo Nordisk, Sanofi, Eli Lilly, Merck, and AstraZeneca. These companies are involved in the development, production, and marketing of drugs used to treat endocrine and metabolic disorders. Show Less Read more